Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen S.A. – 2023 Consolidated Financial Statements
Attachment
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
- 15 February 2024 - 1 mins read
Ipsen S.A. – 2023 Consolidated Financial Statements
Attachment
Related Press Releases
10 June 2024
12 mins read
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
07 June 2024
6 mins read
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
06 June 2024
5 mins read
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
05 June 2024
7 mins read
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis
02 May 2024
5 mins read
Ipsen appoints Keira Driansky as EVP, President of North America
24 April 2024
7 mins read
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
22 April 2024
5 mins read
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
02 April 2024
7 mins read
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
13 February 2024
14 mins read
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
08 February 2024
8 mins read